Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as a Highly Expressed, Clinically Relevant Target for Gynecologic Cancers at SGO 2026

B MUC16 is the highest-expressing ADC target in ovarian cancer, at least two-fold higher than other emerging targets MUC16 is highly and stably expressed in…
posteditor
posteditor
Articles: 16137

Other News